• Magazine
    • Current Issue
    • Past Issues
    • Subscribe
    • Change Mailing Address
    • Surveys
    • Guidelines for Authors
    • Editorial Calendar and Deadlines
    • Dynamic Chiropractic
      • Newspaper
      • Subscription
    • The American Chiropractor
      • Magazine
  • Practice
    • Business Tips
    • Chiropractic Schools
    • Clinical & Technique
    • Ebooks
    • Ecourses
    • Sponsored Content
    • Infographics
    • Quizzes
    • Wellness & Nutrition
    • Podcast
  • Content Hubs
  • Products & Services
    • View Products & Services Directory
    • Browse Buyers Guide
    • Submit a Product
    • Vendor Login
  • Datebook
    • View Events
    • Post an Event
    • Become an Events Poster
  • Advertise
    • Advertising Information
    • Media Kit
    • Contact Us

Your Online Practice Partner

Chiropractic Economics
Your Online Practice Partner
Advertise Subscribe
  • Home
  • News
  • Webinars
  • Chiropractic Research
  • Students/New DCs

Erchonia receives first-ever FDA 510(K) pain indication using a violet laser

Chiropractic Economics Staff October 8, 2019

violet laser treatment

On Oct. 7, Erchonia Corporation, the global leader in the manufacturing and development of low-level laser therapy technology (“3LT®”), announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) market clearance to market its EVRL low -level laser for the temporary relief of chronic neck and shoulder pain of musculoskeletal origin.

Erchonia continues to be the pioneer in developing new FDA indications for laser therapy; previously violet light has been solely for use on dermatological conditions, i.e acne. With this new indication, the EVRL becomes that first and only violet laser (405nm) to receive FDA market clearance for use on an indication related to pain.

The treatment success for neck and shoulder pain is not new to Erchonia, as the company received the first FDA market clearance for laser therapy in 2002, based off (2) level 1 blinded and controlled clinical studies using red laser only for the treatment of chronic neck and shoulder pain. (K012580)

About the EVRL Study

The purpose of this clinical study was to determine the effectiveness of the Erchonia® EVRL, when both the red and violet diodes are activated simultaneously. The lasers were active for 13 minutes and no other therapies were used in conjunction. The subject’s pain recording was recorded immediately after treatment using a 0 to 100 Visual Analog Pain Scale (VAS). The FDA predetermined the individual subject success as a 30% or greater decrease in pain. The EVRL laser far exceeded criteria as ALL enrolled subjects experienced a reduction in pain following treatment, with an average pain reduction of 50%. Subjects also experienced an increase in range of motion (ROM) and subject satisfaction. Study results are published in Medical Devices: Evidence and Research 2019:12 319–325.

“What makes the study results more impressive is the average duration of pain was 76.58 months. These subjects were living with chronic pain for an average of 6+ years, and with just a single treatment from the Erchonia EVRL Laser, they experienced a significant reduction in pain,” comments Steven Shanks, president of Erchonia.

The study was pre-established as a non-inferiority study (equivalency or superiority) of the EVRL in red/violet diode combination therapy compared to the red diode only therapy as based upon the comparative data from the 2001 Erchonia clinical trial. Based off the results, the EVRL red/Violet combination outperformed the FDA market cleared red laser with respect to change in pain scores and improvement in shoulder range of motion.

“The addition of the violet light application with the red light has revolutionized my approach to treating musculoskeletal injuries. The lights synergy has increased my clinical outcomes substantially,” comments Robert Silverman, DC.

Erchonia would like to thank Robert G. Silverman and Albert Comey for their dedication to the science of low-level laser therapy and for helping document this clinical study.

About Erchonia Corporation

Based in Melbourne, Florida, family-owned Erchonia is the global leader in the manufacturing and development of low-level laser therapy technology (“3LT”). From humble beginnings in a garage in 1996, Erchonia today develops and sells the most advanced, non-invasive 3LT medical equipment on the market in over 50 countries. In fact, Erchonia first low-level laser market clearance in 2002 prompted the FDA to create a new device category: NHN Biostimulation lasers. With 17 different market clearances from the FDA, Erchonia remains passionately committed to effective, research-based 3LT solutions for a wide variety of conditions — from managing chronic pain to promoting fat loss. For more information, please visit erchonia.com.

Related Posts

  • Biotone, Biofreeze collaborate to support massage therapy studentsBiotone, Biofreeze collaborate to support massage therapy students
  • Carlson Laboratories improves MSM Sulfur supplementCarlson Laboratories improves MSM Sulfur supplement
  • Palmer College of Chiropractic students tour Standard Process Inc.Palmer College of Chiropractic students tour Standard Process Inc.
  • Athletes shine at Olympic trials with the help of chiropracticAthletes shine at Olympic trials with the help of chiropractic
  • In Memory of Stephen L. Quinto, Founder of Natural Immunogenics Corp. (Sovereign Silver & Sovereign Copper)In Memory of Stephen L. Quinto, Founder of Natural Immunogenics Corp. (Sovereign Silver & Sovereign Copper)

Filed Under: Industry News

Current Issue

Issue 10 cover

Get Exclusive Content! Join our email list

Follow Us

  • Facebook
  • X (Twitter)
  • Instagram
  • LinkedIn
  • YouTube logoYouTube logoYouTube

Compare Subscriptions

Dynamic Chiropractic

The American Chiropractor

8430 Enterprise Circle, Suite 200

Lakewood Ranch, FL 34202

Phone 800-671-9966

CONTACT US »

Privacy Policy | Terms of Service

Copyright © Chiropractic Economics, A Gallagher Company. All Rights Reserved.

SUBSCRIBE TO THE MAGAZINE

Get Chiropractic Economics magazine
delivered to your home or office. Just
fill out our form to request your FREE
subscription for 20 issues a year,
including two annual Buyers Guides.

SUBSCRIBE NOW »

Chiropractic Economics Issue 10 - 2025 Summer Product Buyers Guide